Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SETD7 | Q8WTS6 | 2/20 | 0.47 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.42 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.42 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.42 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.38 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.38 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.38 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.38 |
| ▸ | SPR | P35270 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28719794 | 1.00 | SETD7 (0.47) | SETD7PDK1PDK2PDK3PDK4 | |
| SCHEMBL28719848 | 1.00 | SETD7 (0.47) | SETD7PDK1PDK2PDK3PDK4 | |
| SCHEMBL3395559 | 0.88 | SETD7 (0.47) | SETD7PDK1PDK2PDK3PDK4 | |
| SCHEMBL18701809 | 0.88 | SETD7 (0.49) | SETD7USP2SMN1; SMN2NR1H2MEN1 | |
| SCHEMBL4336794 | 0.86 | SETD7 (0.52) | SETD7USP2SMN1; SMN2NR1H2MEN1 | |
| SCHEMBL28055264 | 0.84 | SETD7 (0.51) | SETD7USP2SMN1; SMN2NR1H2MEN1 | |
| SCHEMBL28060463 | 0.83 | SETD7 (0.50) | SETD7USP2SMN1; SMN2NR1H2MEN1 | |
| SCHEMBL26666330 | 0.83 | SETD7 (0.50) | SETD7USP2SMN1; SMN2NR1H2MEN1 | |
| SCHEMBL17560369 | 0.83 | SETD7 (0.50) | SETD7USP2SMN1; SMN2NR1H2MEN1 | |
| SCHEMBL17560370 | 0.83 | SETD7 (0.50) | SETD7USP2SMN1; SMN2NR1H2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110088098-B | Quinazolinone PARP-1 inhibitor and preparation method, pharmaceutical composition and application thereof | 中国医学科学院药物研究所 | 2022-04-15 | — | — | CN | disclosed |
| US-20100249411-A1 | Stereoselective Alkylation of Chiral 2-Methly-4 Protected Piperazines | WU WENXUE | 2010-09-30 | — | — | US | disclosed |
| US-7745626-B2 | Stereoselective alkylation of chiral 2-methyl-4-protected piperazines | SCHERING CORPORATION (US) | 2010-06-29 | — | — | US | disclosed |
| EP-2141143-A2 | Stereoselective alkylation of chiral 2-methyl-4 protected piperazines | SCHERING CORPORATION (US) | 2010-01-06 | — | — | EP | disclosed |
| EP-2141153-A2 | Stereoselective alkylation of chiral 2-methyl-4 protected piperazines | SCHERING CORPORATION (US) | 2010-01-06 | — | — | EP | disclosed |
| EP-1490346-B1 | STEREOSELECTIVE ALKYLATION OF CHIRAL 2-METHYL-4-PROTECTED PIPERAZINES | SCHERING CORP (US) | 2009-12-02 | — | — | EP | disclosed |
| US-20050171120-A1 | Stereoselective alkylation of chiral 2-methyl-4-protected piperazines | WU WENXUE (US) | 2005-08-04 | — | — | US | disclosed |
| US-6872826-B2 | Stereoselective alkylation of chiral 2-methyl-4-protected piperazines | SCHERING CORPORATION (US) | 2005-03-29 | — | — | US | disclosed |
| US-20030208074-A1 | Stereoselective alkylation of chiral 2-methyl-4-protected piperazines | SCHERING CORPORATION | 2003-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171120-A1 | Stereoselective alkylation of chiral 2-methyl-4-protected piperazines | AZI2, ALKBH5, DNMT1 | SETD7 145/4885PDK1 4138/4885PDK2 2863/4885 |
| US-20030208074-A1 | Stereoselective alkylation of chiral 2-methyl-4-protected piperazines | AZI2, DNMT1, ALKBH5 | SETD7 147/4885PDK1 4010/4885PDK2 2784/4885 |
| US-20100249411-A1 | Stereoselective Alkylation of Chiral 2-Methly-4 Protected Piperazines | ALKBH5, AZI2, PNMT | SETD7 126/4885PDK1 4262/4885PDK2 3049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.